Zhejiang Tianyu Pharmaceutical Co. Ltd., of Taizhou, China, is no longer authorized to manufacture valsartan for drugs marketed in the EU following the suspension of its certificate of suitability (CEP). The European Directorate for the Quality of Medicines and Healthcare suspended the certificate after low levels of a potential carcinogen, N-nitrosodimethylamine (NDMA), were found in the API produced by the company.